For Immediate Release
PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
SAN DIEGO, February 9, 2009 - PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced today that it has recently completed a collaboration with LigoCyte Pharmaceuticals, Inc. Under the collaborative agreement, PacificGMP produced master cell and baculovirus banks and will provide storage services under cGMP (current good manufacturing practices) standards for LigoCyte’s norovirus vaccine program. Furthermore, PacificGMP conducted the services under an accelerated timeline.
“We are pleased that LigoCyte chose PacificGMP to produce the master cell and baculovirus banks that will be used to produce their next-generation, intra-muscular norovirus vaccine candidate,” said Leigh N. Pierce, President of PacificGMP. “The timeline specified in this agreement further demonstrates the time saving advantages of single-use technology as we were able to quickly initiate this project in order to assist LigoCyte in maintaining its program schedule.”
About PacificGMP, Inc.
PacificGMP is a contract manufacturing organization (CMO) and leader in the industry in single-use technology for development and manufacturing of biologics. Single-use technology eliminates the risk of cross-contamination, has fewer system requirements and significantly reduces the time required to initiate production. Benefits to clients include rapid project turnaround and the most cost effective solution in the industry. PacificGMP partners with drug developers by providing a range of cGMP and non-GMP services from early stages of process design, development and scale-up, to preclinical and clinical manufacturing. More information can be found by visiting the Company’s web site at www.pacificgmp.com.
About LigoCyte Pharmaceuticals
LigoCyte Pharmaceuticals is a private biopharmaceutical company focused on the development of innovative vaccine products based on the company’s proprietary virus-like particle platform technology. LigoCyte’s lead candidate recently completed a Phase I clinical trial. The vaccine is being developed for the prevention of norovirus gastroenteritis, an illness that causes an estimated 64,000 hospitalizations and 900,000 clinical visits among children annually in the U.S, according to the CDC. LigoCyte also has a novel influenza vaccine in preclinical development that has, notably, demonstrated protection in ferrets across multiple influenza subtypes with a single VLP antigen. Incorporated in 1998, LigoCyte has 45 employees and is located in Bozeman, Montana. Please visit www.ligocyte.com for more information.
Contact:
Gary L. Pierce, General Counsel and Chief Business Officer of PacificGMP LLC, phone: 1-858-550-4094, garyp@pacificgmp.com
###
|
